Abstract
Despite the availability of the BCG vaccine and chemotherapy, tuberculosis (TB) remains a leading infectious killer worldwide. The recent rise of TB and especially the alarming increase of drug-resistant TB call for urgent need to develop new anti-TB drugs. Lengthy chemotherapy and increasing emergence of drug-resistant strains pose a significant problem for effective control. The need for a lengthy TB therapy is a consequence of the presence of persistent Mycobacterium tuberculosis, not effectively killed by current anti-TB agents. A list of new drug candidates along with proposed targets for intervention is described. Recent advances in the knowledge of the biology of the organism and the availability of the genome sequence provide a wide range of novel targets for drug design. Gene products involved in controlling vital aspects of mycobacterial metabolism, persistence, virulence and cell wall synthesis would be attractive targets. It is expected that the application of functional genomics tools, s uch as microarray and proteomics, in combination with modern approaches, such as structure-based drug design and combinatorial chemistry to biology-based targets, will lead to the development of new drugs that are not only active against drug-resistant TB but also can shorten the course of TB therapy.
Keywords: Tuberculosis drug, Tb therapy, Mycobacterium tuberculosis, isoniazid, pyrazinamide, ethionamide, p-aminosalicylic acid, rifampin, ethambutol, cycloserine
Current Drug Targets
Title: Tuberculosis Drug Targets
Volume: 3 Issue: 2
Author(s): Ying Zhang and L. Mario Amzel
Affiliation:
Keywords: Tuberculosis drug, Tb therapy, Mycobacterium tuberculosis, isoniazid, pyrazinamide, ethionamide, p-aminosalicylic acid, rifampin, ethambutol, cycloserine
Abstract: Despite the availability of the BCG vaccine and chemotherapy, tuberculosis (TB) remains a leading infectious killer worldwide. The recent rise of TB and especially the alarming increase of drug-resistant TB call for urgent need to develop new anti-TB drugs. Lengthy chemotherapy and increasing emergence of drug-resistant strains pose a significant problem for effective control. The need for a lengthy TB therapy is a consequence of the presence of persistent Mycobacterium tuberculosis, not effectively killed by current anti-TB agents. A list of new drug candidates along with proposed targets for intervention is described. Recent advances in the knowledge of the biology of the organism and the availability of the genome sequence provide a wide range of novel targets for drug design. Gene products involved in controlling vital aspects of mycobacterial metabolism, persistence, virulence and cell wall synthesis would be attractive targets. It is expected that the application of functional genomics tools, s uch as microarray and proteomics, in combination with modern approaches, such as structure-based drug design and combinatorial chemistry to biology-based targets, will lead to the development of new drugs that are not only active against drug-resistant TB but also can shorten the course of TB therapy.
Export Options
About this article
Cite this article as:
Zhang Ying and Amzel Mario L., Tuberculosis Drug Targets, Current Drug Targets 2002; 3 (2) . https://dx.doi.org/10.2174/1389450024605391
DOI https://dx.doi.org/10.2174/1389450024605391 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Use of Biologics for Psoriasis in Asia-Pacific Region
Current Rheumatology Reviews Assessing the Effectiveness of a Telemedicine Initiative in Clinical Management of Children Living with HIV/AIDS in Maharashtra, India
Current HIV Research Fracture Risk Associated with Use of Antibiotics
Current Drug Safety Update on the Principles and Novel Local and Systemic Therapies for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Mycobacterial Shikimate Pathway Enzymes as Targets for Drug Design
Current Drug Targets Novel Applications of Recombinant Lactic Acid Bacteria in Therapy and in Metabolic Engineering
Recent Patents on Biotechnology Serial Extraction Technique of Rich Antibacterial Compounds in <i>Sargassum cristaefolium</i> Using Different Solvents and Testing their Activity
Current Bioactive Compounds Beneficial Effects of Liposomal Formulations of Lichen Substances: A Review
Current Drug Delivery Bioactive Peptides from Marine Sources as Potential Anti-Inflammatory Therapeutics
Current Protein & Peptide Science Substituted Naphthalen-1-yl-Acetic Acid Hydrazides: Synthesis, Antimicrobial Evaluation and QSAR Analysis
Medicinal Chemistry Review of Current Chemoinformatic Tools for Modeling Important Aspects of CYPsmediated Drug Metabolism. Integrating Metabolism Data with Other Biological Profiles to Enhance Drug Discovery
Current Drug Metabolism Reproductive Health and Family Planning Needs Among HIV-Infected Women in Sub-Saharan Africa
Current HIV Research Bioisosters of β-Lactams as Anti-Infectives
Current Medicinal Chemistry - Anti-Infective Agents Molecular Dynamics and Structural Studies of the Ets Domain-DNA Complexes
Current Bioinformatics Antimicrobial Properties of Various Psychotropic Drugs Against Broad Range Microorganisms
Current Psychopharmacology Flavonoids Acting on DNA Topoisomerases: Recent Advances and Future Perspectives in Cancer Therapy
Current Medicinal Chemistry In Search of Drug Targets for Mycobacterium tuberculosis
Infectious Disorders - Drug Targets Dihydropyrimidinones Scaffold as a Promising Nucleus for Synthetic Profile and Various Therapeutic Targets: A Review
Current Organic Synthesis Attack on the Scourge of Tuberculosis: Patented Drug Targets
Recent Patents on Anti-Infective Drug Discovery Editorial: Molecular Scenarios Behind Infectious Diseases
Current Medicinal Chemistry